Skip to main navigation Skip to search Skip to main content

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg and 0.4 mg as an Adjunctive Therapy

Project: Research

Project Details

StatusFinished
Effective start/end date11/1/12 → 10/30/15

Funding

  • Covance: $29,059.02